UNIVERSITE FRANCOIS RABELAIS DE TOURS;CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS
发明人:
申请号：
ARP170101706
公开号：
AR108844A1
申请日:
2017.06.21
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
1. Immunomelting proteins referred to in this paper include at least two kinds of peptides: (a) at the C-terminal (terminal).The first peptide consists of amino acid sequences of proteins or M proteins separated from strains isolated from human hepatitis B virus.This protein or protein M is separated from its N-terminal.(b) At the N-terminal end,The second peptide consists of amino acid sequences, including at least one transmembrane domain and shell control sequence, and a protein selected from a strain isolated from Zika virus, either from the encapsulated protein or from fusion peptide, including E and C encapsulated proteins. PRM protein. Claim 9: Nucleic acid molecules encoded by molten proteins in accordance with any of the 1 to 8 claims. Goal 11: Viral subparticlesNon-infectious and immune proteins comprise the following proteins: a protein consisting of a locally dominant position of the surface antigen of a isolated hepatitis B virus strain and at least one combined protein to satisfy any requirement of 1-8. Claim 13: Fusion proteins in any of the 1 to 8 claims,For the prevention and/or treatment of hepatitis B and/or Zika virus-related infections. Requirement 14: A cell line expressing subviral particles.Claim No. 11 refers to non-infectivity and immunity.La presente se refiere a una proteína de fusión inmunogénica que comprende al menos los dos péptidos siguientes: a) en el extremo C-terminal, un primer péptido constituido: por la secuencia de aminoácidos de la proteína S o de la proteína M de una cepa aislada del virus humano de la hepatitis B (HBV), esta proteína S o proteína M es delecionada o no en su extremo N-terminal, y b) en el extremo N-terminal, un segundo péptido constituido: por la secuencia de aminoácidos de al menos un dominio transmembrana y del ectodominio de al menos una proteína de una cepa aislada del virus del Zika elegida entre la proteína de envoltura E o un péptido de fusión que comprende la proteína de envoltura E y la proteína prM
